FabRx is a spin-out company from the University College London (UCL) holding a unique leadership position in the development of 3D printing for fabricating medicines (a segment 3DPMN has covered in the past). The company employs different 3D printing technologies such as FDM, SLA and now SLS to manufacture what it refers to as “Printlets” (3D printed tablets), with a wide range of pharmaceutical excipients.
Some time ago FabRx included a Sintratec Kit SLS printer in their armamentarium. The company choose the Sintratec Kit because of its open parameters.
“In order to print medicines, very specific parameter settings are required since drug and excipients would be completely degraded otherwise. With the Sintratec Kit the parameters like laser speed and material temperature could be finely adjusted to exactly meet our requirements,”
FabRx’s Fabrizio Fina
A novelty in the pharma industry
3D printed medicines with almost any drug compound in a range of shapes, sizes, colours and textures can be produced to make them more attractive to various patient groups, particularly the young or the elderly, facilitating compliance of the treatment.
FabRx is the first commercial research group in the world investigating SLS technology to print oral formulations. The company recently published their work in the “International journal of Pharmaceutics” and following the surprisingly successful results they purchased a second Sintratec Kit
“We are currently working on identifying and formulating a medicine that could take advantage of SLS 3D printing with the aim of bringing our product to the market. We also recently won the TCT Start Up Award 2017 with this project. The Sintratec Kit allows us a whole new approach to the development of new medicines.” said Fina.